Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Biollaz

Showing results (1-10 of 151) with videos related to

Pageof 16
Sort By:
Schweizerische Medizinische Wochenschrift|April 30, 1988
[The treatment of cardiac insufficiency with vasodilators]J Biollaz, A Munafo
Praxis|February 12, 1998
[Importance and limitations of metabolic drug half-life]T Buclin, J Biollaz
Journal of Chromatography|May 30, 1989
High-performance liquid chromatographic assay with fluorometric detection for flecainide and its major metabolites in urine and serumA Munafo, J Biollaz
Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis|February 16, 1993
[Follow-up drug treatment in the practitioner's office]A Munafo, J Biollaz
Revue Medicale Suisse|May 19, 2005
[Multiple diseases: should we treat them all?]J Biollaz, T Buclin
Revue Medicale Suisse|May 19, 2005
[The blood-brain barrier: recent insights]T Buclin, J Biollaz
Therapeutische Umschau. Revue Therapeutique|August 1, 1987
[Choice of cardiac antiarrhythmia agents]L Kappenberger, J Biollaz
Clinical Pharmacokinetics|May 1, 1992
Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapyM Burnier, J Biollaz
Praxis|June 4, 1999
[The medical advisor: a friend to count on?]J Biollaz, T Buclin
Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology|January 1, 1979
Renal function tests in experimental toxicity studiesJ Diézi, J Biollaz
Pageof 16

Showing results (1-10 of 151) with videos related to

Sort By:
Pageof 16
Schweizerische Medizinische Wochenschrift|April 30, 1988
[The treatment of cardiac insufficiency with vasodilators]J Biollaz, A Munafo
Praxis|February 12, 1998
[Importance and limitations of metabolic drug half-life]T Buclin, J Biollaz
Journal of Chromatography|May 30, 1989
High-performance liquid chromatographic assay with fluorometric detection for flecainide and its major metabolites in urine and serumA Munafo, J Biollaz
Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis|February 16, 1993
[Follow-up drug treatment in the practitioner's office]A Munafo, J Biollaz
Revue Medicale Suisse|May 19, 2005
[Multiple diseases: should we treat them all?]J Biollaz, T Buclin
Revue Medicale Suisse|May 19, 2005
[The blood-brain barrier: recent insights]T Buclin, J Biollaz
Therapeutische Umschau. Revue Therapeutique|August 1, 1987
[Choice of cardiac antiarrhythmia agents]L Kappenberger, J Biollaz
Clinical Pharmacokinetics|May 1, 1992
Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapyM Burnier, J Biollaz
Praxis|June 4, 1999
[The medical advisor: a friend to count on?]J Biollaz, T Buclin
Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology|January 1, 1979
Renal function tests in experimental toxicity studiesJ Diézi, J Biollaz
Pageof 16